ALLO - Allogene Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ALLO price evolution
ALLO
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $93.45 | $79.54 | $165.05 | $120.22 |
| Short term investments | $365.54 | $396.26 | $337.2 | $361.29 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $459.12 | $473.45 | $502.1 | $481.46 |
| Long term investments | $3.65 | $37.53 | $62.5 | $53.91 |
| Property, plant & equipment | $163.18 | $181.47 | $186.7 | $191.81 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.72 | $238.87 | $268.87 | $265.41 |
| Total investments | $369.19 | $433.79 | $399.7 | $415.2 |
| Total assets | $642.84 | $712.33 | $770.97 | $746.87 |
| Current liabilities | ||||
| Accounts payable | $5.9 | $6.21 | $10.23 | $14.69 |
| Deferred revenue | $0.09 | $0.24 | $0.23 | $0.27 |
| Short long term debt | ||||
| Total current liabilities | $37.08 | $37.64 | $54.72 | $59.59 |
| Long term debt | $90.1 | $91.82 | $93.51 | |
| Total noncurrent liabilities | $93.53 | $91.59 | $93.34 | $95.02 |
| Total debt | $90.1 | $91.82 | $93.51 | |
| Total liabilities | $130.6 | $129.22 | $148.06 | $154.61 |
| Shareholders' equity | ||||
| Retained earnings | -$1562.23 | -$1473.99 | -$1412.67 | -$1334.68 |
| Other shareholder equity | -$0.95 | -$2.41 | -$3.85 | -$5.93 |
| Total shareholder equity | $512.23 | $583.1 | $622.91 | $592.26 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $93.45 | $72.2 | $183.61 | $192.8 |
| Short term investments | $365.54 | $455.42 | $283.99 | $644.56 |
| Net receivables | $1.7 | $1.8 | $1.9 | $2.8 |
| Inventory | ||||
| Total current assets | $459.12 | $528.82 | $471.32 | $845.13 |
| Long term investments | $3.65 | $71.97 | $370.18 | $207.95 |
| Property, plant & equipment | $163.18 | $196.43 | $181.02 | $160.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.72 | $288.25 | $567.31 | $382.7 |
| Total investments | $369.19 | $527.38 | $654.17 | $852.5 |
| Total assets | $642.84 | $817.08 | $1038.63 | $1227.83 |
| Current liabilities | ||||
| Accounts payable | $5.9 | $13.89 | $10.26 | $10.39 |
| Deferred revenue | $0.09 | $0.89 | $0.42 | $38.99 |
| Short long term debt | ||||
| Total current liabilities | $37.08 | $54.52 | $48.17 | $94.32 |
| Long term debt | ||||
| Total noncurrent liabilities | $93.53 | $96.69 | $74.05 | $53.89 |
| Total debt | ||||
| Total liabilities | $130.6 | $151.21 | $122.23 | $148.21 |
| Shareholders' equity | ||||
| Retained earnings | -$1562.23 | -$1235.98 | -$903.35 | -$646.34 |
| Other shareholder equity | -$0.95 | -$9.93 | -$2.57 | $0.27 |
| Total shareholder equity | $512.23 | $665.87 | $916.41 | $1079.62 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | -$0.04 | $0.04 | $0.04 | $0.05 |
| Cost of revenue | ||||
| Gross Profit | -$0.04 | $0.04 | $0.04 | $0.05 |
| Operating activities | ||||
| Research & development | $54.66 | $45.98 | $62.04 | $80.24 |
| Selling, general & administrative | $17.22 | $17.04 | $18.52 | $18.88 |
| Total operating expenses | $85.13 | $63.02 | $80.56 | $99.12 |
| Operating income | -$85.17 | -$62.98 | -$80.52 | -$99.07 |
| Income from continuing operations | ||||
| EBIT | -$89.26 | -$61.31 | -$77.99 | -$98.7 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$89.26 | -$61.31 | -$77.99 | -$98.7 |
| Income (for common shares) | -$89.26 | -$61.31 | -$77.99 | -$98.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.1 | $0.24 | $38.49 | |
| Cost of revenue | ||||
| Gross Profit | $0.1 | $0.24 | $38.49 | |
| Operating activities | ||||
| Research & development | $242.91 | $256.39 | $220.18 | $192.99 |
| Selling, general & administrative | $71.67 | $79.31 | $74.11 | $65.26 |
| Total operating expenses | $327.83 | $335.69 | $294.28 | $258.24 |
| Operating income | -$327.74 | -$335.45 | -$255.79 | -$258.24 |
| Income from continuing operations | ||||
| EBIT | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Income (for common shares) | -$327.26 | -$332.63 | -$257 | -$250.22 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$89.26 | -$61.31 | -$77.99 | -$98.7 |
| Operating activities | ||||
| Depreciation | $3.48 | $3.57 | $3.64 | $3.51 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $15.23 | $15.35 | $16.59 | $18.77 |
| Total cash flows from operations | -$53.71 | -$55.53 | -$61.86 | -$66.64 |
| Investing activities | ||||
| Capital expenditures | -$0.18 | -$0.01 | -$0.29 | -$1.03 |
| Investments | $67.64 | -$34.26 | $17.45 | $113.97 |
| Total cash flows from investing | $67.46 | -$34.27 | $17.16 | $112.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.15 | $4.29 | $89.52 | $1.73 |
| Net borrowings | ||||
| Total cash flows from financing | $0.15 | $4.29 | $89.52 | $1.73 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $13.91 | -$85.51 | $44.83 | $48.03 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Operating activities | ||||
| Depreciation | $14.2 | $14.29 | $10.45 | $7.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $65.95 | $83.6 | $80.82 | $65.26 |
| Total cash flows from operations | -$237.73 | -$220.52 | -$184.81 | -$115.09 |
| Investing activities | ||||
| Capital expenditures | -$1.52 | -$5.19 | -$21.45 | -$65.96 |
| Investments | $164.81 | $111.35 | $185.1 | -$439.17 |
| Total cash flows from investing | $163.29 | $106.16 | $163.66 | -$505.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $95.69 | $2.95 | $11.96 | $633.59 |
| Net borrowings | ||||
| Total cash flows from financing | $95.69 | $2.95 | $11.96 | $633.59 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $21.25 | -$111.41 | -$9.19 | $13.38 |
News
Fundamentals
| Market cap | $591.93M |
|---|---|
| Enterprise value | $498.49M |
| Shares outstanding | 168.64M |
| Revenue | $95.00K |
|---|---|
| EBITDA | -$313.07M |
| EBIT | -$327.26M |
| Net Income | -$327.26M |
| Revenue Q/Q | -193.62% |
| Revenue Y/Y | -60.91% |
| P/E ratio | -1.81 |
|---|---|
| EV/Sales | 5.25K |
| EV/EBITDA | -1.59 |
| EV/EBIT | -1.52 |
| P/S ratio | 6.23K |
| P/B ratio | 1.15 |
| Book/Share | 3.04 |
| Cash/Share | 0.55 |
| EPS | -$1.94 |
|---|---|
| ROA | -45.56% |
| ROE | -56.66% |
| Debt/Equity | 0.25 |
|---|---|
| Net debt/EBITDA | -0.12 |
| Current ratio | 12.38 |
| Quick ratio | 12.38 |